Ever Supreme Bio Technology Co., Ltd (TPEX: 6712)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
171.50
-0.50 (-0.29%)
Dec 19, 2024, 1:30 PM CST
-2.00%
Market Cap 13.96B
Revenue (ttm) 844.86M
Net Income (ttm) 254.33M
Shares Out 80.67M
EPS (ttm) 3.15
PE Ratio 55.00
Forward PE n/a
Dividend 5.45 (3.15%)
Ex-Dividend Date n/a
Volume 121,260
Open 170.00
Previous Close 172.00
Day's Range 170.00 - 172.00
52-Week Range 166.00 - 215.00
Beta 0.28
Analysts n/a
Price Target n/a
Earnings Date Mar 28, 2025

About Ever Supreme Bio Technology

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6712
Full Company Profile

Financial Performance

In 2023, Ever Supreme Bio Technology's revenue was 758.39 million, an increase of 20.86% compared to the previous year's 627.51 million. Earnings were 539.40 million, an increase of 168.74%.

Financial Statements

News

There is no news available yet.